



CONTACT:

Investor Relations

David Isserman

877-895-5647

IR@nutrapharma.com

**NUTRA PHARMA ANNOUNCES PARTNERSHIP WITH WORLD AIDS
CAMPAIGN**

BOCA RATON, Fla. -- Feb. 28, 2007 -- Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has partnered with the European Union-based World AIDS Campaign to help raise awareness about global AIDS initiatives aimed at eradicating the disease by 2015.

“We are pleased to announce our recent partnership with the World AIDS Campaign,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “This organization serves an important role in the global AIDS community and we are proud to be one of the United States partners,” he added.

The World AIDS Campaign was founded in 1997 in Amsterdam and is currently managed by the Joint United Nations Programme on HIV/AIDS (UNAIDS). The Organization is funded in part by the Ford Foundation, Soros Foundation, and the Netherlands-based AIDS Fonds.

About Nutra Pharma Corp.

Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.

<http://www.NutraPharma.com>

This press release contains forward-looking statements. The words or phrases "would

be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The partnership with the World AIDS Campaign should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

###